Published in final edited form as:

J Am Chem Soc. 2018 January 31; 140(4): 1211–1214. doi:10.1021/jacs.7b11299.

Stereoselective Dynamic Cyclization of Allylic Azides: Synthesis of Tetralins, Chromanes, and Tetrahydroquinolines

Matthew R. Porter, Rami M. Shaker, Cristian Calcanas, and Joseph J. Topczewski*

Department of Chemistry, University of Minnesota Twin Cities, Minneapolis, Minnesota 55455, United States

Abstract

This report describes the stereoselective synthesis of 3-azido-tetralins, -chromanes, and -tetrahydroquinolines via a tandem allylic azide rearrangement/Friedel–Crafts alkylation. Exposure of allylic azides with a pendant trichloroacetimidate to catalytic quantities of AgSbF_6 proved optimal for this transformation. This cascade successfully differentiates the equilibrating azide isomers, providing products in excellent yield and selectivity (>25 examples, up to 94% yield and >25:1 dr). In many cases, the reactive isomer is only a trace fraction of the equilibrium mixture, keenly illustrating the dynamic nature of these systems. We demonstrate the utility of this process via a synthesis of hasubanan.

Tetralins, chromanes, and tetrahydroquinolines represent privileged structural motifs present in pharmaceuticals, agrochemicals, and natural products. Many feature an amino substituent at the C-3 position (Figure 1). These molecules display a wide range of activity including treatments or potential treatments for cancer, pain, depression, thrombosis, Parkinson's disease, and malaria.^{1–9} Due to this rich history, numerous synthetic methods can generate these systems including cyclization,^{10–15} annulation,^{16,17} cycloaddition,^{18,19} partial reduction,^{20,21} and others.^{6,22–24} Presented herein is a distinctive carbon–carbon bond forming reaction that generates these privileged motifs with the required 3-amino-functionality by manipulating the allylic azide rearrangement.

Allylic azides exist as an equilibrating mixture of isomers. This was first noted by Winstein, who documented the rate of isomerization for prenyl and crotyl azides.²⁵ Since then, chemists have struggled to exploit this rearrangement synthetically because of difficulty differentiating the azide isomers.^{26–33} Only a few reports accomplish selective elaboration. The Craig lab reported a tandem Claisen rearrangement (Figure 2a).³⁴ Selectivity was achieved by orchestrating a second irreversible sigmatropic process. The Aubé lab reported a

*Corresponding Author: jtopczew@umn.edu.

Supporting Information

The Supporting Information is available free of charge on the ACS Publications website at DOI: 10.1021/jacs.7b11299. Experimental procedures and characterization data (PDF) Crystallographic data for compound **2d** (CIF)

ORCID

Joseph J. Topczewski: 0000-0002-9921-5102

Notes

The authors declare no competing financial interest.

tandem Schmidt reaction that attained selectivity through cyclization and achieved diastereocontrol via chairlike intermediates (Figure 2b).³⁵ Recently, we initiated a program to explore the allylic azide rearrangement's potential.³⁶ We reported the first example of enantioselective resolution of symmetric systems.³⁷ Herein, we report a synergistic approach that combines the use of proximal functionality with a complexity generating cyclization. By merging these tactics (Figure 2c), we obtain selectivity on unsymmetric systems and accomplished a tandem Friedel–Crafts alkylation (Figure 2d). This reaction results in the highest combined yield and diastereoselectivity reported to date for a dynamic allylic azide functionalization. We demonstrate the utility of this chemistry through a succinct synthesis of hasubanan.

Our strategy incorporated a second proximal allylic functional group. When the azide is proximal (Figure 2c, OIM group, isomers **i** *E* and **iv** *Z*), the second group would be primary. However, when the azide is distal (Figure 2c, ii *trans* isomer), the second group would be allylic and therefore substantially more reactive. We chose a trichloroacetimidate because it could be readily activated under electrophilic conditions, such as those for glycosylation,^{38,39} rearrangement,^{40–45} or substitution.^{46–50} A pendent arene might intercept the putative electrophile in a Friedel–Crafts alkylation. Ring closure could potentially proceed from either allylic terminus and the tether would enforce regioselectivity. Imposing selectivity by these combined approaches could afford a highly chemo-, site-, regio-, and diastereoselective protocol for the synthesis of 3-azido-tetralins, -chromanes, and -tetrahydroquinolines (X = CH₂, O, or N-PG, respectively; Figure 2d).

We began with allylic azide **1a** (Table 1). This allylic azide exists as an equilibrium mixture (1.3:1.0:0.7:trace *E:trans:Z:cis*, representations shown in Figure 2c). The reactive *trans* isomer is only ~30% of the mixture. We exposed azide **1a** to a number of activators, including Lewis acids (entries 1–3), Brønsted acids (entries 4–7), and transition metal complexes (entries 8–10). Most conditions led to decomposition (entry 1), poor selectivity (entries 2,3), or poor reactivity (entries 3–5, 8, and 9). Control experiments, conducted after an initial hit with cationic gold(I) (entry 10), provided encouraging results with silver salts. Silver salts with noncoordinating counterions were efficacious (entries 12–14) and those with more lipophilic counterions provided superior results. Conditions with catalytic AgSbF₆ are mild, high yielding, and highly stereoselective (entry 14). In a control experiment, 2,6-di-*tert*-buty-4-methyl-pyridine inhibited the reaction (entry 15). The reaction is slow in ethanol stabilized chloroform (entry 16) or in the presence of deliberately added water (entry 17). These observations implicate general acid catalysis.⁵¹ The reaction was tolerant to ambient conditions (entry 18).

We explored the scope of this cyclization with a series of allylic azides (Scheme 1). Common substituents on the aryl ring were tolerated (H, OMe, Cl, or Br, **2a–2d**). Conveniently, derivative **2d** provided diffraction quality crystals. Analysis unambiguously demonstrated the relative configuration of **2d**. Other compounds were assigned by analogy to compound **2d**. Different tethers were tolerated. The 3-methyl group is not required for diastereoselectivity (**2e**). Azide **2e** maps onto biologically active 3-amino-tetralins (Figure 1). Interestingly, imidate **1f** exists almost exclusively as the unreactive isomers by ¹H NMR analysis (>99% *E* and *Z*). The reactive *trans* isomer is destabilized by *syn*-pentane

interactions with the geminal methyl groups. However, this does not inhibit reactivity and compound **2f** was isolated in acceptable yield. This observation supports Curtin–Hammett kinetics with rate limiting aromatic substitution. Moving the methyl group to the center of the allylic system eroded the dr (1.7:1 for compound **2g**). We propose a putative stereochemical model based on chair like transition states (Figure 3). The pathways differ in the orientation of the vinyl group. The major diastereomer could arise from the pseudoequatorial orientation. When the hydrogen atom is replaced with a methyl (**1g**), then the relative energy approaches unity and diastereoselectivity is reduced (**2g**). Lastly, a group larger than methyl was permitted in the backbone (**2h**).

Incorporating a heteroatom into the system would generate valuable heterocycles. A number of ethereal allylic azides were converted into chromanes in high yield and selectivity (Scheme 2, **4a**). Activating groups such as methyl (**4b**) or methoxy (**4c**) were competent as were compounds with a halogen substituent (entries **4d–4f**). Poly substituted aromatics were tolerated (entries **4g–4i**). These results are gratifying because the heteroatom is a basic site that could slow catalysis. The proximal oxygen would inductively reduce the stability of a cationic intermediate and could disrupt the azide equilibrium.⁵² These substrates also indicate limitations in this method. The formation of **4j** was slow and imidate decomposition occurred. Chromane **4k** was isolated as a mixture of regioisomers (1.4:1).

We explored aniline derived allylic azides that lead to azido-tetrahydroquinolines (Scheme 3). Several azides were prepared with varying arene substitution and *N*-protecting group. All imidate precursors in this class contained less than 10% of the reactive *trans* isomer at equilibrium. Gratifyingly, these azides readily afforded tetrahydroquinolines in good yield with high dr. A number of aryl-substituents were tolerated (entries **6a–6f**).

We conducted the reaction on a gram scale (Scheme 4). Using >1 g of imidate **1a** provided tetralin **2a** in 82% yield. The product could be oxidized under the Upjohn protocol⁵³ to afford diol **7**. Reduction using palladium on carbon provided amine **8**. Selective reduction of the azide with LiAlH₄ afforded amine **9**. The protocol of Evans⁵⁴ was used to form pyrrolidine **10**. Cycloaddition provided triazole **11**.

We were emboldened to attempt a synthesis of hasubanan (Scheme 5). Hasubanan is the parent structure of the hasubanan alkaloids, a large family of botanical natural products. Members of this family have been studied synthetically and display diverse biological activities.^{55–60} The vicinal tetrasubstituted centers in the core provide a significant synthetic challenge. To the best of our knowledge, there are no prior reported syntheses of the parent molecule hasubanan. We began with ester **12**, which is directly available from commercial material.^{61–63} Reduction and partial reoxidation afforded aldehyde **13**, which was elaborated by Corey–Chaykovsky epoxidation. Epoxide **14** was opened regioselectively with NaN₃ in acetone/water yielding allylic azide **15**. Imidate **16** was isolated after activation with trichloroaceto-nitrile. The key cyclization proceeded as expected to establish the necessary stereochemical relationship and the quaternary carbon center. The minor diastereomer was not observed. The final functional group manipulation was accomplished through reduction and ring closure with dicyclohexyl borane.⁵⁴ This last step clearly illustrates the advantage

of using an allylic azide in this synthesis because the final amine functionality was established with concurrent C–N bond formation.

In conclusion, we report a tandem allylic azide rearrangement–Friedel–Crafts alkylation. This dynamic cyclization process resolves a mixture of equilibrating allylic azide isomers by exploiting the enhanced reactivity of the allylic electrophile. We demonstrated that this process is general and leads to valuable 3-azido-tetralin, -chromane, and -tetrahydroquinoline hetero-cycles. Furthermore, the products of this reaction are readily diversifiable.

Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

Acknowledgments

We thank Ryan Daley for assistance in the analysis of compound **2d**. Madeline D. Newcomb for creating the cover art associated with this manuscript. Financial support was provided by the University of Minnesota and The American Chemical Society's Petroleum Research Fund (PRF # 56505-DNI1). This research was supported by the National Institute of General Medical Sciences of the National Institutes of Health under Award Number R35GM124718. We also acknowledge NIH Shared Instrumentation Grant #S10OD011952.

References

1. Lin YC, Chang JC, Cheng SY, Wang CM, Jhan YL, Lo IW, Hsu YM, Liaw CC, Hwang CC, Chou CH. *J Agric Food Chem*. 2015; 63:2472. [PubMed: 25694129]
2. Iwata N, Kitanaka S. *J Nat Prod*. 2010; 73:1203. [PubMed: 20586436]
3. Kantarjian HM, O'Brien S, Cortes J. *Clin Lymphoma, Myeloma Leuk*. 2013; 13:530. [PubMed: 23790799]
4. Forster PG, Ghisalberti EL, Jefferies PR, Poletti VM, Whiteside NJ. *Phytochemistry*. 1986; 25:1377.
5. Hall SR, Raston CL, Skelton BW, White AH. *J Chem Soc Perkin Trans*. 1981; 211:1467.
6. Sridharan V, Suryavanshi PA, Menéndez JC. *Chem Rev*. 2011; 111:7157. [PubMed: 21830756]
7. Ward RS. *Nat Prod Rep*. 1999; 16:75.
8. Cragg, GM., Kingston, DGI., Newman, DJ. *Anticancer Agents from Natural Products*. 2nd. CRC Press; 2011.
9. Keller-Juslen C, Kuhn M, Von Wartburg A, Staehelin H. *J Med Chem*. 1971; 14:936. [PubMed: 5165570]
10. Jefferies LR, Cook SP. *Org Lett*. 2014; 16:2026. [PubMed: 24666277]
11. Venning ARO, Bohan PT, Alexanian EJ. *J Am Chem Soc*. 2015; 137:3731. [PubMed: 25746442]
12. Denmark SE, Kornfilt DJP. *J Org Chem*. 2017; 82:3192. [PubMed: 28257203]
13. Shimogaki M, Fujita M, Sugimura T. *J Org Chem*. 2017; 82:11836. [PubMed: 28551992]
14. Mahlthau F, Schuster O, Bach T. *J Am Chem Soc*. 2005; 127:9348. [PubMed: 15984844]
15. Ammann SE, Rice GT, White MC. *J Am Chem Soc*. 2014; 136:10834. [PubMed: 24983326]
16. Reddel JCT, Wang W, Koukounas K, Thomson RJ. *Chem Sci*. 2017; 8:2156. [PubMed: 28507668]
17. Ma X-Y, An X-T, Zhao X-H, Du J-Y, Deng Y-H, Zhang X-Z, Fan C-A. *Org Lett*. 2017; 19:2965. [PubMed: 28514154]
18. Wang L, Wu F, Chen J, Nicewicz DA, Huang Y. *Angew Chem Int Ed*. 2017; 56:6896.
19. Kuwano R, Shige T. *J Am Chem Soc*. 2007; 129:3802. [PubMed: 17352480]
20. Carreño MC, González-López M, Latorre A, Urbano A. *J Org Chem*. 2006; 71:4956. [PubMed: 16776527]
21. Lim CS, Quach TT, Zhao Y. *Angew Chem Int Ed*. 2017; 56:7176.

22. Tsoung J, Krämer K, Zajdlik A, Liébert C, Lautens M. *J Org Chem*. 2011; 76:9031. [PubMed: 21951196]
23. Webster R, Boyer A, Fleming MJ, Lautens M. *Org Lett*. 2010; 12:5418. [PubMed: 21043435]
24. Ye B, Cramer N. *Synlett*. 2015; 26:1490.
25. Gagneux A, Winstein S, Young WG. *J Am Chem Soc*. 1960; 82:5956.
26. Gagnon D, Lauzon S, Godbout C, Spino C. *Org Lett*. 2005; 7:4769. [PubMed: 16209531]
27. Lauzon S, Tremblay F, Gagnon D, Godbout C, Chabot C, Mercier-Shanks C, Perreault S, DeSeve H, Spino C. *J Org Chem*. 2008; 73:6239. [PubMed: 18642871]
28. Maag H, Rydzewski RM. *J Org Chem*. 1992; 57:5823.
29. Vekariya RH, Liu R, Aubé J. *Org Lett*. 2014; 16:1844. [PubMed: 24635056]
30. Feldman AK, Colasson BB, Sharpless KB, Fokin VV. *J Am Chem Soc*. 2005; 127:13444. [PubMed: 16190677]
31. Askin D, Angst C, Danishefsky S. *J Org Chem*. 1985; 50:5005.
32. Cardillo G, Fabbroni S, Gentilucci L, Perciaccante R, Piccinelli F, Tolomelli A. *Org Lett*. 2005; 7:533. [PubMed: 15704887]
33. Takasu H, Tsuji Y, Sajiki H, Hirota K. *Tetrahedron*. 2005; 61:11027.
34. Craig D, Harvey JW, O'Brien AG, White AJP. *Org Biomol Chem*. 2011; 9:7057. [PubMed: 21879133]
35. Liu R, Gutierrez O, Tantillo DJ, Aubé J. *J Am Chem Soc*. 2012; 134:6528. [PubMed: 22490078]
36. Goswami PP, Suding VP, Carlson AS, Topczewski JJ. *Eur J Org Chem*. 2016; 2016:4805.
37. Ott AA, Goshey CS, Topczewski JJ. *J Am Chem Soc*. 2017; 139:7737. [PubMed: 28574252]
38. Schmidt RR, Michel J. *Angew Chem Int Ed Engl*. 1980; 19:731.
39. Wang, Z. *Comprehensive Organic Name Reactions and Reagents*. John Wiley & Sons, Inc; 2010.
40. Adhikari AA, Suzuki T, Gilbert RT, Linaburg MR, Chisholm JD. *J Org Chem*. 2017; 82:3982. [PubMed: 28323428]
41. Anderson CE, Overman LE. *J Am Chem Soc*. 2003; 125:12412. [PubMed: 14531676]
42. Overman LE. *J Am Chem Soc*. 1974; 96:597.
43. Overman LE. *J Am Chem Soc*. 1976; 98:2901.
44. Watson MP, Overman LE, Bergman RG. *J Am Chem Soc*. 2007; 129:5031. [PubMed: 17402733]
45. Kirsch SF, Overman LE, Watson MP. *J Org Chem*. 2004; 69:8101. [PubMed: 15527296]
46. Reznichenko AL, Nguyen HN, Hultsch KC. *Angew Chem Int Ed*. 2010; 49:8984.
47. Arnold JS, Nguyen HM. *J Am Chem Soc*. 2012; 134:8380. [PubMed: 22563701]
48. Zhang Q, Stockdale DP, Mixdorf JC, Topczewski JJ, Nguyen HM. *J Am Chem Soc*. 2015; 137:11912. [PubMed: 26348569]
49. Topczewski JJ, Quinn DM. *Org Lett*. 2013; 15:1084. [PubMed: 23410111]
50. Topczewski JJ, Tewson TJ, Nguyen HMJ. *J Am Chem Soc*. 2011; 133:19318. [PubMed: 22059470]
51. Jiang X, Pan Z, Douglas CJ. *Tetrahedron Lett*. 2015; 56:5324.
52. Packard MH, Cox JH, Suding VP, Topczewski JJ. *Eur J Org Chem*. 2017; 2017:6365.
53. VanRheenen V, Kelly RC, Cha DY. *Tetrahedron Lett*. 1976; 17:1973.
54. Evans DA, Weber AE. *J Am Chem Soc*. 1987; 109:7151.
55. King SM, Herzon SB. *Alkaloids Chem Biol*. 2014; 73:161. [PubMed: 26521650]
56. Calandra NA, King SM, Herzon SB. *J Org Chem*. 2013; 78:10031. [PubMed: 24032758]
57. Jones SB, He L, Castle SL. *Org Lett*. 2006; 8:3757. [PubMed: 16898810]
58. Herzon SB, Calandra NA, King SM. *Angew Chem Int Ed*. 2011; 50:8863.
59. Chuang KV, Navarro R, Reisman SE. *Angew Chem Int Ed*. 2011; 50:9447.
60. Schultz AG, Wang A. *J Am Chem Soc*. 1998; 120:8259.
61. Trost BM, Imi K, Davies IW. *J Am Chem Soc*. 1995; 117:5371.
62. Gärtner D, Stein AL, Grupe S, Arp J, Jacobi von Wangelin A. *Angew Chem Int Ed*. 2015; 54:10545.

63. Li B-J, Xu L, Wu Z-H, Guan B-T, Sun C-L, Wang B-Q, Shi Z-J. *J Am Chem Soc.* 2009; 131:14656. [PubMed: 19788187]

Author Manuscript

Author Manuscript

Author Manuscript

Author Manuscript

Figure 1.
Representative biologically active compounds.

Figure 2.
Selectivity for Allylic Azide Functionalization.

Figure 3.
Putative cyclic stereochemical model.

Scheme 1. Formation of Tetralins 2a–h by Tandem Process^a^aYields reported for isolated material as the average of duplicate trials. The dr was determined by ^1H NMR.

Scheme 2. Formation of Chromanes 4a-l by Tandem Process^a^aYields reported for isolated material as the average of duplicate trials. The dr was determined by ¹H NMR.

Scheme 3. Formation of Tetrahydroquinolines **6a-f**^a^aYields reported for isolated material as the average of duplicate trials. The dr was determined by ^1H NMR.

Scheme 4.
Gram Scale Reaction and Diversification of Product

Scheme 5.
Synthesis of Hasubanan by Tandem Process

Table 1

Optimization of Tandem Rearrangement Friedel-Crafts Alkylation

entry ^a	catalyst	yield % ^b	dr ^c
1	BF ₃ ·OEt ₂	35	28:1
2	Cu(OTf) ₂	75	9:1
3	Zn(OTf) ₂	58	9:1
4	TFA	4	4:1
5	TsOH	4	7:1
6	Tf ₂ NH	80	13:1
7	TrOH	49	7:1
8	PdCl ₂	0	nd
9	[(COP)PdCl] ₂	0	nd
10	JohnPhosAuSbF ₆	75	21:1
11	AgOTs	0	nd
12	AgClO ₄	81	7:1
13	AgOTf	80	7:1
14	AgSbF ₆	92	21:1
15 ^d	AgSbF ₆	3	3:1
16 ^e	AgSbF ₆	55	16:1
17 ^f	AgSbF ₆	71	21:1
18 ^g	AgSbF ₆	77	20:1

^a 0.10 mmol substrate at 0.1 M in CHCl₃ for 24 h.^b Determined by GC-FID analysis using naphthalene as an internal standard. Values are the average of duplicate trials.^c Determined by GC-FID analysis.^d 20 mol % 2,6-di-*tert*-butyl-4-methylpyridine was added. nd = not determined.^e The reaction was conducted in CHCl₃ stabilized with EtOH.^f 5 equiv of water were deliberately added.^g The reaction was conducted under ambient conditions.